Patents by Inventor Mike Lizarzaburu

Mike Lizarzaburu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230339886
    Abstract: The present disclosure provides compounds of Formula IA and Formula IB and their pharmaceutical compositions as selective agonists of REV-ERB-?: where R1, R2, R3, R4, R5, RX1, RX2, nA, nB, X, Y, and Z are described herein. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.
    Type: Application
    Filed: June 23, 2021
    Publication date: October 26, 2023
    Applicants: University of Florida Research Foundation, Incorporated, SHANGPHARMA INNOVATION INC.
    Inventors: Theodore Mark Kamenecka, Kevin Greenman, Laura Solt, Yuanjun He, Mike Lizarzaburu, Brett C. Bookser
  • Publication number: 20220340629
    Abstract: The present invention provides myosin derived peptides, variants and derivative compounds that are anti-coagulant. Also provided in the invention are antibodies that specifically target the peptides or epitopes presented thereon. Further provided in the invention are methods directed to using the anti-coagulant compounds described herein in therapeutic applications, e.g., inhibiting myosin-supported prothrombin activation to reduce the risk of acute trauma coagulopathy in post-trauma patients or inhibiting cardiac myosin-supported prothrombin activation to reduce the risk of coronary thrombosis.
    Type: Application
    Filed: May 25, 2022
    Publication date: October 27, 2022
    Inventors: John H. Griffin, Hiroshi Deguchi, Weijun Shen, Sam Lear, Elsa Pflimlin, Yvonne Marie Angell, Mike Lizarzaburu
  • Patent number: 11274105
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: March 15, 2022
    Assignee: AMGEN INC.
    Inventors: Gwenaella Rescourio, Ana Gonzalez Buenrostro, Sean P. Brown, Mike Lizarzaburu, Julio Medina, Salman Yojiro Jabri, Daqing Sun, Scott Preston Simonovich, Xuelei Yan, Yihong Li, Yosup Rew
  • Publication number: 20210047344
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: March 4, 2019
    Publication date: February 18, 2021
    Applicant: AMGEN INC.
    Inventors: Gwenaella RESCOURIO, Ana GONZALEZ BUENROSTRO, Sean P. BROWN, Mike LIZARZABURU, Julio MEDINA, Salman Yojiro JABRI, Daqing SUN, Scott Preston SIMONOVICH, Xuelei YAN, Yihong LI, Yosup REW
  • Patent number: 8022061
    Abstract: Compounds having formula I: where A1, A2, L, V, W, R1, R2, R3, R4 and R5 are as described herein, compositions thereof, and their use for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions are provided herein.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: September 20, 2011
    Assignee: Amgen Inc.
    Inventors: Yasuyuki Ogawa, Ryo Okuyama, Satoshi Shibuya, Narihiro Toda, Zhaodan Cao, Zice Fu, Xiaolin Hao, Yong-Jae Kim, Leping Li, Sarah E. Lively, Mike Lizarzaburu, Hui Tian, Ming Yu
  • Publication number: 20080153778
    Abstract: Compounds having formula I: where A1, A2, L, V, W, R1, R2, R3, R4 and R5 are as described herein, compositions thereof, and their use for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions are provided herein.
    Type: Application
    Filed: October 9, 2007
    Publication date: June 26, 2008
    Inventors: Yasuyuki Ogawa, Ryo Okuyama, Satoshi Shibuya, Narihiro Toda, Zhaodan Cao, Zice Fu, Xiaolin Hao, Yong-Jae Kim, Leping Li, Sarah E. Lively, Mike Lizarzaburu, Hui Tian, Ming Yu
  • Patent number: 7125885
    Abstract: The present invention provides compounds having the formula: wherein R1, R2, R, R? and the subscript p are described herein. The compounds are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. Pharmaceutical compositions and methods of using these compounds for the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor, such as eating disorder, obesity, anxiety disorders and mood disorders are also provided.
    Type: Grant
    Filed: August 26, 2004
    Date of Patent: October 24, 2006
    Assignee: Amgen Inc.
    Inventors: Xiaoqi Chen, Pingchen Fan, Juan Jaen, Leping Li, Mike Lizarzaburu, Jeffrey Thomas Mihalic, Stephen Joseph Shuttleworth
  • Publication number: 20060199796
    Abstract: The present invention relates to the compounds of Formula I, their preparation and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful, for example, for the treatment and prevention of obesity, obesity-related disorders and eating disorders.
    Type: Application
    Filed: August 12, 2005
    Publication date: September 7, 2006
    Applicant: Amgen Inc.
    Inventors: Xi Chen, Xiaoqi Chen, Richard Connors, Kang Dai, Ying Fu, Juan Jaen, Yong-Jae Kim, Leping Li, Mike Lizarzaburu, Jeffrey Mihalic, Stephen Shuttleworth
  • Publication number: 20050148617
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. In particular, the compounds of the invention are useful in the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders.
    Type: Application
    Filed: August 26, 2004
    Publication date: July 7, 2005
    Inventors: Xiaoqi Chen, Pingchen Fan, Juan Jaen, Leping Li, Mike Lizarzaburu, Jeffrey Mihalic, Stephen Shuttleworth
  • Patent number: 6809104
    Abstract: Compounds having the formula: wherein L is a bond or (C1-C4)alkylene, R″ is hydrogen or (C1-C8)alkyl, and R1, R2, R4, R, R′, and the subscript n are as described herein, are provided, which are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. Pharmaceutical compositions and methods of using these compounds for the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor, such as eating disorders, obesity, anxiety disorders and mood disorders, are also provided.
    Type: Grant
    Filed: November 6, 2002
    Date of Patent: October 26, 2004
    Assignee: Tularik Inc.
    Inventors: Xiaoqi Chen, Pingchen Fan, Juan Jaen, Leping Li, Mike Lizarzaburu, Jeffrey Thomas Mihalic, Stephen Joseph Shuttleworth
  • Publication number: 20030176694
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. In particular, the compounds of the invention are useful in the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders.
    Type: Application
    Filed: November 6, 2002
    Publication date: September 18, 2003
    Inventors: Xiaoqi Chen, Pingchen Fan, Juan Jaen, Leping Li, Mike Lizarzaburu, Jeffrey Thomas Mihalic, Stephen Joseph Shuttleworth